← United States · All US Insider Profiles
US INSIDER PROFILE · NON-SCORING RESEARCH
Wong Hing C
Chief Executive Officer | Officer
Identity: SEC reporting-owner CIK · Reporting-owner CIK: 0001866258
Purchase history
- Companies traded
- 1
- Purchases · 12M
- 2
- Purchases · 24M
- 4
- Average purchase
- $671.4K
- Median purchase
- $110.3K
- Gross purchase value
- $2.7M
Companies: HCW Biologics Inc.
4 SEC accession(s) · 0 joint-owner event(s). Values are reported Form 4 transaction values in USD.
Qualifying purchase disclosures
| Published | Company | Ticker | Role | Reported value | SEC source |
|---|---|---|---|---|---|
| 2026-07-31 | HCW Biologics Inc. | HCWB | Chief Executive Officer | Officer | $60.1K | Open filing |
| 2026-05-27 | HCW Biologics Inc. | HCWB | Chief Executive Officer | Officer | $160.6K | Open filing |
| 2025-05-20 | HCW Biologics Inc. | HCWB | Chief Executive Officer | Officer | $60.0K | Open filing |
| 2025-05-09 | HCW Biologics Inc. | HCWB | Chief Executive Officer | Officer | $2.4M | Open filing |
Post-purchase outcomes
Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 4Small Sample | 100.0% (4/4) | 50.0% (2/4) | -4.5% | +4.2% | -13.9% |
| 20D | 4Small Sample | 100.0% (4/4) | 25.0% (1/4) | -28.2% | -25.0% | -47.8% |
| 60D | 3Small Sample | 100.0% (3/3) | 0.0% (0/3) | -64.3% | -62.4% | -83.6% |
| 120D | 2Small Sample | 100.0% (2/2) | 0.0% (0/2) | -70.1% | -70.1% | -82.3% |
Research patterns
- First purchase in 12M
- 1/3
- Large purchase ≥ $100k
- 2/4
- Cluster buying · 15D
- 4/4
- Buying the dip
- 4/4
Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.
Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.